Bortezomib-Based Regimens Used as Induction in Newly Diagnosed Multiple Myeloma (Ndmm) Patients Eligible for Stem Cell Transplantation (Sct)The Cost-Utility Analysis
Value in Health- United Kingdom
doi 10.1016/j.jval.2014.03.1340
Full Text
Abstract
Available in
Date
May 1, 2014
Authors
Publisher
Elsevier BV